Literature DB >> 1882108

Reversible T-wave abnormality in severe acute asthma: an electrocardiographic sign of severity.

J Efthimiou1, A B Hassan, O Ormerod, M K Benson.   

Abstract

Reversible electrocardiographic (ECG) abnormalities are well recognized in severe acute asthma. Inferior lead T-wave abnormalities have only rarely been reported, and their frequency and significance have not been well documented. We studied 70 consecutive patients with severe acute asthma on admission to hospital and during recovery, in order to examine the frequency and natural history of such changes and to document their relationship to the severity of the attack. Twenty-two patients (34%) had inferior lead T-wave inversion on ECGs performed within 1 h of admission (group 1), whereas the rest did not (group 2). Apart from sinus tachycardia this was the most common ECG abnormality. Patients with inferior T-wave inversion were found to have more severe asthma in terms of degree of pulsus paradoxus, peak expiratory flow rate, forced expiratory volume in 1 s and arterial blood oxygen tension. Ten group 1 and ten group 2 patients underwent two-dimensional echocardiography during the acute phase of their illness and during recovery. Six (60%) group 1 patients showed echocardiographic evidence of right ventricular pressure overload compared with only one (10%) patient in group 2 (P less than 0.02). Following recovery, voluntary hyperventilation and exercise testing in ten group 1 patients failed to reproduce the ECG changes seen on admission. Reversible inferior lead T-wave abnormalities may occur in the severe acute asthma and appear to be related to the severity of the attack.

Entities:  

Mesh:

Year:  1991        PMID: 1882108     DOI: 10.1016/s0954-6111(06)80079-x

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  1 in total

1.  T-wave inversion in diabetic ketoacidosis with normokalemia in an adolescent.

Authors:  Trupti Kale; Hitesh Agrawal; Ramesh Pandit; Zahra Naheed
Journal:  Pediatr Cardiol       Date:  2012-07-18       Impact factor: 1.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.